Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market

Summary

GBI Research, the leading business intelligence provider, has released its latest research “Targeted Therapeutics- Advancement in Gene Therapy and Stem Cell Therapy will Drive the Market”. The report provides in-depth analysis of the major targeted therapeutics. The Market Drivers and Restraints for all the types of Targeted Therapeutics (TT) are analyzed. The report provides comprehensive assessment of key pipeline therapies in the TT segment. The profiles of key promising molecules in the pipeline are mentioned. The regulatory Landscape is analyzed with focus on European and the US scenario. The regulatory landscape details about the major agencies for gene and stem cell therapies. The report profiles all the key companies dealing in TT with main focus on their deals involving M&A and licensing deals.

GBI Research finds that TT is the need of the hour for biotech and pharmaceutical companies to recover from the loss of revenue by patent expiry of conventional blockbuster drugs. Thus key pipeline molecules and key deals will help the companies to make a better future strategy.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research’s team of industry experts.

The report gives insight about the key deals which have taken place between biopharmaceutical companies and their influence. Reasons for considering strategic consolidation as the main objective of the companies have been mentioned. The major types of TT include small molecule drugs, protein/peptide therapeutics, monoclonal antibody therapeutics, RNA interference, gene therapy and stem cell therapy. The market drivers and restraints for these six classes are mentioned. From a commercial perspective there is a huge unmet medical need in difficult to treat diseases like cancer and autoimmune diseases. The unmet need is due to the lack of effective and efficacious therapies based on conventional mode of research. TT has the potential to satisfy this unmet need by being more efficacious, effective and safe. The strategic M&A deals and licensing deals of key companies such as Eli Lilly, Forest Laboratories, Hoffmann La-Roche, Isis Pharmaceuticals, J&J, Pfizer , Biogen, Antisoma and others are analyzed.

Scope

The scope of this report includes -
- Description of major types of TT with key market drivers and restraints.
- Analysis of the leading pipeline therapies which will define the future of TT market.
- Factors driving small molecule drugs, peptide/protein drugs, MAbs, RNA interference therapeutics, gene and stem cell therapy are analyzed.
- Key Regulatory Landscape is detailed for understanding the approval procedure of TT with main focus on gene and stem cell therapy.
- Major companies dealing in TT are profiled and their M&A and Licensing deals are mentioned.
- Key companies studied in this report are Eli Lilly, Pfizer, J&J, Hoffmann La- Roche, Biogen, Isis Pharmaceuticals and Antisoma.

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Identify the advantages of TT and understand the potential that it can capture.
- Align your product portfolio to the TT market segment with high growth potential.
- Develop market-entry and market expansion strategies by identifying the leading TT segments poised for strong growth.
- Understand the key risks and issues which TT is facing and key solutions in development to address these issues.
- Develop key strategic initiatives by understanding the key focus areas with respect to pipeline portfolio of leading companies.
- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps and lead to revenue generation.
- Identify key players best positioned to take advantage of TT market potential.
1 Table of Contents 3
1.1 List of Tables 5
1.2 List of Figures 5
2 Targeted Therapeutics: Introduction 6
2.1 GBI Research Guidance 6
3 Targeted Therapeutics: Overview 7
3.1 Introduction 7
3.2 Targeted Therapy is the Need of the Hour 7
3.2.1 High Side Effects and Toxic Effects of Conventional Therapy 7
3.2.2 Variable Efficacy Rate of Conventional Drugs at the Affected Site 7
3.2.3 Resistance Developed to Conventional Drugs Used to Treat Infections 7
3.3 Targeted Therapeutics Market Drivers and Restraints 8
3.3.1 Targeted Therapeutics Market Drivers 8
3.3.2 Targeted Therapeutics Market Restraints 9
4 Targeted Therapeutics: Major Types of Targeted Therapeutics 10
4.1 Small Molecules 10
4.1.1 Overview 10
4.2 Innovative Small Molecule Therapeutics Market Drivers and Restraints 12
4.2.1 Small Molecule Therapeutics Market Drivers 12
4.2.2 Innovative Small Molecule Therapeutics Market Restraints 12
4.2.3 Profiles of Key Pipeline Molecules 13
4.3 Proteins/Peptide Drugs 23
4.3.1 Overview 23
4.4 Proteins/Peptide Drugs Therapeutics Market Drivers and Restraints 25
4.4.1 Peptides/Protein Drug Therapeutics Market Drivers 25
4.4.2 Peptides/Protein Drug Therapeutics Market Restraints 25
4.4.3 Profiles of Key Pipeline Molecules 26
4.5 Monoclonal Antibodies (MAbs) and Antibody Like Structures 30
4.5.1 Overview 30
4.6 Monoclonal Antibody Therapeutics, Market Drivers and Restraints 33
4.6.1 Monoclonal Antibody Therapeutics Market Drivers 33
4.6.2 Global Monoclonal Antibody Market Restraints 35
4.6.3 Profiles of Key Pipeline Molecules (MAb) 35
4.7 RNA Interference 43
4.7.1 Overview 43
4.8 RNA Interference Therapeutics Market Drivers and Restraints 43
4.8.1 RNA Interference Therapeutics Market Drivers 43
4.8.2 RNA Interference Therapeutics Market Restraints 44
4.8.3 Profiles of Key Pipeline Molecules (RNA) 45
4.9 Stem Cell Therapies 53
4.9.1 Overview 53
4.10 Stem Cell Therapeutics Market Drivers and Restraints 54
4.10.1 Stem Cell Therapeutics Market Drivers 54
4.10.2 Stem Cell Therapeutics Market Restraints 55
4.10.3 Profile of Key Late Stage Therapies 56
4.11 Gene Therapy 58
4.11.1 Overview 58
4.12 Gene Therapy Market Drivers and Restraints 58
4.12.1 Gene Therapy Market Drivers 59
4.12.2 Gene Therapy Market Restraints 59
4.12.3 Key Pipeline Candidates 60
5 Targeted Therapeutics: Regulatory Landscape 69
5.1 The US Regulatory Landscape Scenario 69
5.1.1 National Institute for Health (NIH) 69
5.1.2 FDA 69
5.2 EU Regulatory Landscape Scenario 70
5.2.1 Committee for Advanced Therapies (CAT) 70
6 Targeted Therapeutics: Competitive Landscape 72
6.1 Antisoma 72
6.1.1 Overview 72
6.1.2 Key Deals 72
6.2 AVI BioPharma 72
6.2.1 Overview 72
6.2.2 Key Deals 73
6.3 Biogen 73
6.3.1 Overview 73
6.3.2 Key Deals 74
6.4 Cephalon 74
6.4.1 Overview 74
6.4.2 Key Deals 75
6.5 Eli Lilly 76
6.5.1 Overview 76
6.5.2 Key Deals 76
6.6 Forest Laboratories 78
6.6.1 Overview 78
6.6.2 Key Deals 78
6.7 Genmab 79
6.7.1 Overview 79
6.7.2 Key Deals 79
6.8 Gilead Sciences 80
6.8.1 Overview 80
6.8.2 Key Deals 80
6.9 Hoffmann La- Roche (Genentech) 82
6.9.1 Overview 82
6.9.2 Key Deals 82
6.10 Isis Pharmaceuticals 84
6.10.1 Overview 84
6.10.2 Key Deals 84
6.11 Johnson and Johnson (J&J) 86
6.11.1 Overview 86
6.11.2 Key Deals 87
6.12 Mesoblast Limited 90
6.12.1 Overview 90
6.12.2 Key Deals 90
6.13 Pfizer 90
6.13.1 Overview 90
6.13.2 Key Deals 90
6.14 UCB 93
6.14.1 Overview 93
6.14.2 Key Deals 93
7 Targeted Therapeutics Market - Appendix 94
7.1 Market Definitions 94
7.2 List of Abbreviations 94
7.3 Research Methodology 98
7.3.1 Coverage 98
7.3.2 Secondary Research 98
7.3.3 Primary Research 99
7.3.4 Expert Panel Validation 99
7.4 Contact Us 99
7.5 Disclaimer 99
7.6 Sources 100

1.1 List of Tables
Table 1: Key Small Molecule Drugs Used For Targeted Therapeutics and Their Indications, 2010 10
Table 2: Key Small Molecule Drugs, Global, Sales Value ($m), 2007-2009 11
Table 3: Key Protein/Peptide Drugs, Generic Names and Approved Indications, 2010 23
Table 4: Key Protein/Peptide Drugs, Global, Sales Value ($m), 2007-2009 24
Table 5: Key Monoclonal Antibodies (MAbs) and Their Approved Indications 30
Table 6: Key Monoclonal Antibodies, Global, Sales Value ($m), 2007-2009 31
Table 7: List of Key EMA Directives and Guidelines for GTMPs 71

1.2 List of Figures
Figure 1: Targeted Therapeutics, Global, Market Drivers and Restraints, 2010 8
Figure 2: Key Small Molecule Drugs, Global Sales ($m), 2007- 2009 10
Figure 3: Small Molecule Therapeutics, Global, Market Drivers and Restraints, 2010 12
Figure 4: Key Protein/Peptide Drugs, Global Sales ($m), 2007-2009 23
Figure 5: Protein/Peptide Drug Therapeutics, Global, Market Drivers and Restraints, 2010 25
Figure 6: Key Monoclonal Antibodies, Global, Sales Value ($m), 2007-2009 31
Figure 7: Monoclonal Antibody Therapeutics, Global, Market Drivers and Restraints, 2010 33
Figure 8: RNA Interference Therapeutics, Global, Market Drivers and Restraints, 2010 43
Figure 9: Types Of Stem Cells, Depending Upon Their Potential 53
Figure 10: Stem Cell Therapeutics, Global, Market Drivers and Restraints, 2010 54
Figure 11: Gene Therapy, Global, Market Drivers and Restraints, 2010 58
Figure 12: Definition of Advanced Therapy Medicinal Products by the European Commission 70

Companies Mentioned
Antisoma
AVI BioPharma
Biogen
Cephalon
Eli Lilly
Forest Laboratories
Genmab
Gilead Sciences
Hoffmann La- Roche (Genentech)
Isis Pharmaceuticals
Johnson and Johnson (J&J)
Mesoblast Limited
Pfizer
UCB